Alida Benfante

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6515330/publications.pdf

Version: 2024-02-01

713013 623188 55 597 14 21 h-index citations g-index papers 56 56 56 883 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Does the frequency of switching inhalers represent a predictive factor of exacerbation in asthma?. Journal of Asthma, 2022, 59, 370-377.	0.9	2
2	Effectiveness of benralizumab in severe eosinophilic asthma: Distinct subâ€phenotypes of response identified by cluster analysis. Clinical and Experimental Allergy, 2022, 52, 312-323.	1.4	19
3	Management of severe asthma during the first lockdown phase of SARS-CoV-2 pandemic: Tips for facing the second wave. Pulmonary Pharmacology and Therapeutics, 2022, 73-74, 102083.	1.1	4
4	Transient asymptomatic bradycardia and Remdesivir in COVID-19 patients. Minerva Medica, 2022, , .	0.3	1
5	A 79-year-old-man with SARS-CoV-2 pneumonia and unusual pulmonary co-infection. Minerva Respiratory Medicine, 2022, 61, .	0.1	1
6	Comparison between Suspected and Confirmed COVID-19 Respiratory Patients: What Is beyond the PCR Test. Journal of Clinical Medicine, 2022, 11, 2993.	1.0	2
7	The prevalence of sleep impairments and predictors of sleep quality among patients with asthma. Journal of Asthma, 2021, 58, 481-487.	0.9	17
8	Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression. Journal of Asthma and Allergy, 2021, Volume 14, 163-173.	1.5	39
9	Severe asthma at COVID-19 time: what is new on biologic therapies. Minerva Medica, 2021, 112, 114-117.	0.3	8
10	PREVALENCE OF ARTERIAL HYPERTENSION AND CHARACTERISTICS OF NOCTURNAL BLOOD PRESSURE PROFILE OF ASTHMA PATIENTS ACCORDING TO THERAPY AND SEVERITY OF THE DISEASE: THE BADA STUDY. Journal of Hypertension, 2021, 39, e136.	0.3	0
11	Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4371-4380.e4.	2.0	37
12	The impact of SARS-COV2 pandemic on the management oF IPF patients: Our narrative experience. Pulmonary Pharmacology and Therapeutics, 2021, 69, 102038.	1.1	2
13	The potential role of SP-D as an early biomarker of severity of asthma. Journal of Breath Research, 2021, 15, 041001.	1.5	3
14	Interstitial Lung Disease in Elderly Rheumatoid Arthritis Patients. Drugs and Aging, 2020, 37, 11-18.	1.3	13
15	Management of suspected COVID-19 patients in a low prevalence region. Chronic Respiratory Disease, 2020, 17, 147997312096184.	1.0	4
16	Prevalence of Arterial Hypertension and Characteristics of Nocturnal Blood Pressure Profile of Asthma Patients According to Therapy and Severity of the Disease: The BADA Study. International Journal of Environmental Research and Public Health, 2020, 17, 6925.	1.2	9
17	The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians. Journal of Clinical Medicine, 2020, 9, 2397.	1.0	6
18	Severe asthma and COVID-19: lessons from the first wave. Journal of Asthma, 2020, , 1-7.	0.9	9

#	Article	IF	Citations
19	Fever and dyspnoea in a tracheostomised patient. Breathe, 2020, 16, 200115.	0.6	O
20	Urinary Incontinence in Chronic Obstructive Pulmonary Disease: A Common Co-morbidity or a Typical Adverse Effect?. Drugs and Aging, 2019, 36, 799-806.	1.3	17
21	Are biological drugs effective and safe in older severe asthmatics?. Expert Opinion on Drug Safety, 2019, 18, 369-380.	1.0	11
22	Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661988812.	1.0	12
23	Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics. World Allergy Organization Journal, 2019, 12, 100081.	1.6	11
24	Impact of age on the efficacy of anti-IL-5 monoclonal antibodies in severe asthmatics. , 2019, , .		0
25	Effects of anti-IL-5 receptor alpha in an ex vivo 3D model of COPD. , 2019, , .		0
26	Serum lipoproteins are not associated with the severity of asthma. Pulmonary Pharmacology and Therapeutics, 2018, 50, 57-61.	1.1	3
27	Inhalation therapy in the next decade: Determinants of adherence to treatment in asthma and COPD. Monaldi Archives for Chest Disease, 2018, 88, 886.	0.3	17
28	Sleep Disturbances in COPD are Associated with Heterogeneity of Airway Obstruction. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2018, 15, 350-354.	0.7	10
29	Dynamic hyperinflation during the 6-min walk test in severely asthmatic subjects. ERJ Open Research, 2018, 4, 00143-2017.	1.1	8
30	The anti-inflammatory properties of tiotropium. Lancet Respiratory Medicine, the, 2018, 6, e37.	5.2	7
31	Serum surfactant protein D and exhaled nitric oxide as biomarkers of early lung damage in systemic sclerosis. Minerva Medica, 2018, 109, 71-78.	0.3	9
32	Asthma management in a specialist setting: Results of an Italian Respiratory Society survey. Pulmonary Pharmacology and Therapeutics, 2017, 44, 83-87.	1.1	11
33	How to unveil chronic respiratory diseases in clinical practice? A model of alliance between general practitioners and pulmonologists. Pulmonary Pharmacology and Therapeutics, 2017, 44, 106-110.	1.1	4
34	Arterial stiffness in symptomatic smokers with normal lung function. ERJ Open Research, 2017, 3, 00037-2017.	1.1	1
35	OSACO: an observational study in asthma-COPD overlap syndrome (ACOS). , 2017, , .		0
36	The use of ICS/LABA (extra-fine and non-extra-fine) in elderly asthmatics. Therapeutics and Clinical Risk Management, 2016, Volume 12, 1553-1562.	0.9	4

#	Article	IF	CITATIONS
37	How Effective and Safe Is Bronchial Thermoplasty in "Real Life―Asthmatics Compared to Those Enrolled in Randomized Clinical Trials?. BioMed Research International, 2016, 2016, 1-3.	0.9	6
38	Asthma in the elderly: a different disease?. Breathe, 2016, 12, 18-28.	0.6	57
39	Pharmacological Management of Elderly Patients with Asthma–Chronic Obstructive Pulmonary Disease Overlap Syndrome: Room for Speculation?. Drugs and Aging, 2016, 33, 375-385.	1.3	5
40	Asthmatics with high levels of serum surfactant protein D have more severe disease. European Respiratory Journal, 2016, 47, 1864-1867.	3.1	16
41	Serum Surfactant Protein D as a Marker of Asthma Severity. Chest, 2016, 150, 473-474.	0.4	4
42	The Arg/Arg polymorphism of the ADRB2 is associated with the severity of allergic asthma. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 1251-1252.	2.0	3
43	Challenges in the pharmacological treatment of geriatric asthma. Expert Review of Clinical Pharmacology, 2016, 9, 917-926.	1.3	11
44	The geriatric asthma: pitfalls and challenges. Asthma Research and Practice, 2016, 2, 2.	1.2	6
45	Serum surfactant protein D is a potential biomarker of lung damage in systemic sclerosis. , 2016, , .		0
46	Early Lung Function Abnormalities in Acromegaly. Lung, 2015, 193, 393-399.	1.4	9
47	Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases?. Pulmonary Pharmacology and Therapeutics, 2015, 31, 63-67.	1.1	40
48	Asthma in the older adult: presentation, considerations and clinical management. Expert Review of Clinical Immunology, 2015, 11, 1297-1308.	1.3	15
49	Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD. Patient Related Outcome Measures, 2014, 5, 153.	0.7	25
50	Exhaled nitric oxide is associated with cyclic changes in sexual hormones. Pulmonary Pharmacology and Therapeutics, 2013, 26, 644-648.	1.1	9
51	Airway Distensibility by HRCT in Asthmatics and COPD with Comparable Airway Obstruction. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013, 10, 560-566.	0.7	8
52	Serum low density lipoprotein subclasses inÂasthma. Respiratory Medicine, 2013, 107, 1866-1872.	1.3	29
53	Lung penetration and patient adherence considerations in the management of asthma: role of extra fine formulations. Journal of Asthma and Allergy, $2013, 6, 11$.	1.5	35
54	Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients. Clinical Interventions in Aging, 2013, 8, 1329.	1.3	17

#	Article	IF	CITATIONS
55	The asthma-COPD overlap syndrome (ACOS): hype or reality?. Shortness of Breath, 0, , .	0.0	0